Upgrade to SI Premium - Free Trial

Aclaris Therapeutics (ACRS)

5.64 +0.32 (6.02%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (11/11/26)

Latest Headlines

Aclaris Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference September 3, 2026 8:00 AM - StreetInsider Canaccord Starts Aclaris Therapeutis (ACRS) at Buy September 1, 2026 6:20 AM - StreetInsider Piper Sandler on Aclaris Therapeutis (ACRS): 'Efficacy Differentiation Could Drive Share Re-Rate' August 31, 2026 8:52 AM - StreetInsider Form SCHEDULE 13G/A Aclaris Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P. August 14, 2026 4:44 PM - SEC Filing Form 8-K Aclaris Therapeutics, For: Aug 06 August 6, 2026 5:15 PM - SEC Filing Form S-3ASR Aclaris Therapeutics, August 6, 2026 5:08 PM - SEC Filing Form 10-Q Aclaris Therapeutics, For: Jun 30 August 6, 2026 4:37 PM - SEC Filing FDA grants fast track status to Aclaris drug for lichen planus August 6, 2026 4:36 PM - StreetInsider Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP) August 6, 2026 4:35 PM - StreetInsider Form 8-K Aclaris Therapeutics, For: Aug 06 August 6, 2026 7:15 AM - SEC Filing Aclaris Therapeutics (ACRS) Tops Q2 EPS by 1c August 6, 2026 7:05 AM - StreetInsider Aclaris Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate and Clinical Update August 6, 2026 6:59 AM - StreetInsider Form 4 Aclaris Therapeutics, For: Aug 01 Filed by: Kolbeck Roland Wilhelm August 4, 2026 5:03 PM - SEC Filing Full Article List